The global Multiple System Atrophy (MSA) therapeutics market is expected to grow at a compound annual growth rate (CAGR) of 4.4%, with a current valuation of US$ 137.3 million by 2023. Healthcare technology advancements are expected to drive the market to US$ 211.1 million by 2033.
Multiple system atrophy (MSA) is a neurodegenerative disorder that causes symptoms that affect both the autonomic nervous system and movement. The multiple system atrophy causes are unknown, and most cases are sporadic. The accumulation of alpha-synuclein is a distinguishing feature of MSA.
Preview Next-Level Insights Sample :
https://www.futuremarketinsights.com/reports/sample/rep-gb-16285
Key Takeaways:
- The MSA therapeutics market is expected to reach US$211.1 million by 2033, driven by a CAGR of 4.4%.
- Limited treatment options for MSA highlight the significant need for novel therapies.
- Technological advancements in gene therapy and other areas hold promise for the future of MSA treatment.
- Growing disease awareness is leading to earlier diagnosis and a greater demand for effective treatments.
Competitive Landscape:
Biohaven Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., AstraZeneca plc, Theravance Biopharma, Inc., Merck & Co., Neuropore Therapies Inc, Newron Pharmaceuticals SpA, ProMIS Neurosciences Inc, Stealth BioTherapeutics Corp, Chelsea Therapeutics International, Ltd. are some of the key players in the multiple system atrophy therapeutics industry.
The manufacturers are involved in the production of multiple system atrophy therapeutics in a larger capacity. Research and innovation are also conducted to launch innovative products for multiple system atrophy therapeutics.
Also, some of the key players are acquiring small pharmaceutical companies to increase their production capacity. Suppliers are focusing on expanding their market presence across the world by initiating new product launches and boosting sales.
- In April 2022, ProMIS Neurosciences, Inc. a biotechnology company focused on the discovery and development of potential therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced new milestones in potential therapeutic approaches for ALS.
- In October 2022, Biohaven Ltd. announced advancements in the development of its MoDE extracellular target degrader platform technology licensed from Yale University for various disease indications, including, but not limited to, neurological disorders, cancer, and infectious and autoimmune diseases.
Explore Our Methodology Framework:
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-16285
Key Companies Profiled:
- Biohaven Pharmaceuticals, Inc.
- Sumitomo Dainippon Pharma Co., Ltd.
- AstraZeneca plc
- Theravance Biopharma, Inc.
- Merck & Co.
- Neuropore Therapies Inc
- Newron Pharmaceuticals SpA
- ProMIS Neurosciences Inc
- Stealth BioTherapeutics Corp
- Chelsea Therapeutics International, Ltd.
Key Segments Covered in the Multiple System Atrophy (MSA) Market Industry Survey:
Multiple System Atrophy (MSA) Therapeutics Market by Type:
- Parkinsonian
- Cerebellar
Multiple System Atrophy (MSA) Therapeutics Market by Diagnosis:
- Magnetic Resonance Imaging (MRI)
- Positron Emission Tomography (PET)
- Single Photon Emission Computed Tomography (SPECT)
- Tilt Table Test
- Others
Multiple System Atrophy (MSA) Therapeutics Market by RegionP:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa (MEA)
Obtain In-Depth Market Insights: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/16285
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube